STOCK TITAN
  1. Home
  2. News
  3. THER

THERALINK TECHNOLOGIES - $THER STOCK NEWS

Welcome to our dedicated page for THERALINK TECHNOLOGIES news (Ticker: $THER), a resource for investors and traders seeking the latest updates and insights on THERALINK TECHNOLOGIES stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect THERALINK TECHNOLOGIES's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of THERALINK TECHNOLOGIES's position in the market.

News
Theralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates
Rhea-AI Summary
Theralink Technologies (THER) announces groundbreaking findings from the ISPY-2 trial, revealing new therapeutic options for challenging breast cancers using RPPA technology. The study identified HARPS, a protein biomarker, for more effective stratification of Triple Negative Breast Cancer patients, potentially leading to ~80% response rates compared to the current 30-40%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.29%
Tags
none
-
News
Theralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4
Rhea-AI Summary
Theralink Technologies, Inc. (OTC: THER) and IMAC Holdings, INC (Nasdaq: BACK) have responded to the SEC’s first round of comments on the jointly filed form S-4, a registration statement required for a merger or acquisition. This signifies a major milestone as it moves the transaction forward, creating a well-positioned proteomics pure play focused on the next generation of cancer care and protein analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.18%
Tags
none
-
News
Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor Board
Rhea-AI Summary
Theralink Technologies announces promising results from its partnership with Inova Schar Cancer Institute to integrate Theralink's RPPA technology into Inova's Molecular Tumor Board. The partnership aims to improve treatment selection and patient-tailored therapy regimes by combining genomic and proteomic analysis. Interim results showed a clinical recommendation change for over half of the patients and additional treatment considerations for 59% of the patients. Theralink's proteomics data also revealed a mechanism of resistance for a targeted therapy. Another study highlighted Theralink's ability to measure HER2 abundance in pancreatic tumors. Final study analysis and results are expected in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
none
News
Theralink Announces Filing of Form S-4; Merger with IMAC Holdings Expected During Q4 2023
Rhea-AI Summary
Theralink Technologies announces filing of Form S-4 for merger with IMAC Holdings, creating a new NASDAQ-listed company focused on proteomics testing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
acquisition earnings
-
News
Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
management
-
News
Theralink® Acquires Exclusive Landmark Immunotherapy Patent including Biomarker from Vanderbilt University
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
acquisition
News
Theralink® Technologies Begins Receiving Payments from Third Party Payors for its Advanced Breast Cancer Assay, Achieving Key Milestone
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
none
-
News
Theralink's Exclusive Licensed RPPA Technology for Commercial Laboratory Testing to Assist the White House Cancer Moonshot Initiative
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
none
-
News
Theralink® Technologies Appoints Michael Vallone as Senior Director of Commercialization
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
News
Theralink® Technologies Appoints Seasoned Commercial Leader, Faith Zaslavsky, as President & Chief Operating Officer for its Precision Oncology Company
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
management
Stock THER logo
THERALINK TECHNOLOGIES

OTC:THER

THER Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

THER Stock Data

6.15M
1.07B
82.61%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Golden

About THER

theralink technologies, inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapy products. the company has proprietary rights to immunotherapy platform focusing on prostate and breast cancers. the company's lead product is proscavax, which is in phase 2 clinical trials for the treatment of prostate cancer. it is also developing targeted therapies. theralink technologies, inc. has a partnership with perthera, inc. to facilitate and enhance access to theralink's 32 phosphoprotein panel, the theralink assay, for breast cancer patients. the company was formerly known as oncbiomune pharmaceuticals, inc. and changed its name to theralink technologies, inc. in september 2020. theralink technologies, inc. is based in baton rouge, louisiana.